BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 9548817)

  • 21. Expression profiling of rat femur revealed suppression of bone formation genes by treatment with alendronate and estrogen but not raloxifene.
    Helvering LM; Liu R; Kulkarni NH; Wei T; Chen P; Huang S; Lawrence F; Halladay DL; Miles RR; Ambrose EM; Sato M; Ma YL; Frolik CA; Dow ER; Bryant HU; Onyia JE
    Mol Pharmacol; 2005 Nov; 68(5):1225-38. PubMed ID: 16079270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estrogen and raloxifene stimulate transforming growth factor-beta 3 gene expression in rat bone: a potential mechanism for estrogen- or raloxifene-mediated bone maintenance.
    Yang NN; Bryant HU; Hardikar S; Sato M; Galvin RJ; Glasebrook AL; Termine JD
    Endocrinology; 1996 May; 137(5):2075-84. PubMed ID: 8612550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene.
    Rosati RL; Da Silva Jardine P; Cameron KO; Thompson DD; Ke HZ; Toler SM; Brown TA; Pan LC; Ebbinghaus CF; Reinhold AR; Elliott NC; Newhouse BN; Tjoa CM; Sweetnam PM; Cole MJ; Arriola MW; Gauthier JW; Crawford DT; Nickerson DF; Pirie CM; Qi H; Simmons HA; Tkalcevic GT
    J Med Chem; 1998 Jul; 41(16):2928-31. PubMed ID: 9685230
    [No Abstract]   [Full Text] [Related]  

  • 24. Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands.
    Renaud J; Bischoff SF; Buhl T; Floersheim P; Fournier B; Halleux C; Kallen J; Keller H; Schlaeppi JM; Stark W
    J Med Chem; 2003 Jul; 46(14):2945-57. PubMed ID: 12825935
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity.
    Dodge JA; Lugar CW; Cho S; Short LL; Sato M; Yang NN; Spangle LA; Martin MJ; Phillips DL; Glasebrook AL; Osborne JJ; Frolik CA; Bryant HU
    J Steroid Biochem Mol Biol; 1997 Apr; 61(1-2):97-106. PubMed ID: 9328215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparative study of the effects of genistein, estradiol and raloxifene on the murine skeletal system.
    Sliwiński L; Folwarczna J; Nowińska B; Cegieła U; Pytlik M; Kaczmarczyk-Sedlak I; Trzeciak H; Trzeciak HI
    Acta Biochim Pol; 2009; 56(2):261-70. PubMed ID: 19401787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of estrogen-stimulated growth of uterine leiomyomas by selective estrogen receptor modulators.
    Fuchs-Young R; Howe S; Hale L; Miles R; Walker C
    Mol Carcinog; 1996 Nov; 17(3):151-9. PubMed ID: 8944075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of 3-phenyl-4-[[4-[2-(1-piperidinyl)ethoxy]phenyl]methyl]- 2H-1-benzopyran-7-ol (CHF 4056), a novel nonsteroidal estrogen agonist/antagonist, on reproductive and nonreproductive tissue.
    Galbiati E; Caruso PL; Amari G; Armani E; Ghirardi S; Delcanale M; Civelli M
    J Pharmacol Exp Ther; 2002 Mar; 300(3):802-9. PubMed ID: 11861784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of the selective estrogen receptor modulators, methyl-piperidino-pyrazole (MPP), and raloxifene in normal and cancerous endometrial cell lines and in the murine uterus.
    Davis AM; Ellersieck MR; Grimm KM; Rosenfeld CS
    Mol Reprod Dev; 2006 Aug; 73(8):1034-44. PubMed ID: 16688783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative study of the short-term effects of a novel selective estrogen receptor modulator, ospemifene, and raloxifene and tamoxifen on rat uterus.
    Zheng H; Kangas L; Härkönen PL
    J Steroid Biochem Mol Biol; 2004 Feb; 88(2):143-56. PubMed ID: 15084346
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of SP500263, a novel selective estrogen receptor modulator, on bone, uterus, and serum cholesterol in the ovariectomized rat.
    Sutherland MK; Brady H; Gayo-Fung LM; Leisten J; Lipps SG; McKie JA; O'Leary E; Patnaik N; Anderson DW; Bhagwat SS; Stein B
    Calcif Tissue Int; 2003 Jun; 72(6):710-6. PubMed ID: 14563000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone.
    Willson TM; Norris JD; Wagner BL; Asplin I; Baer P; Brown HR; Jones SA; Henke B; Sauls H; Wolfe S; Morris DC; McDonnell DP
    Endocrinology; 1997 Sep; 138(9):3901-11. PubMed ID: 9275080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selective estrogen receptor modulators: a new category of compounds to extend postmenopausal women's health.
    Goldstein SR
    Int J Fertil Womens Med; 1999; 44(5):221-6. PubMed ID: 10569450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo activation of gene transcription via oestrogen response elements by a raloxifene analogue.
    Engdahl C; Jochems C; Gustafsson JA; van der Saag PT; Carlsten H; Lagerquist MK
    J Endocrinol; 2009 Dec; 203(3):349-56. PubMed ID: 19752149
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of raloxifene on tibia histomorphometry in ovariectomized rats.
    Evans G; Bryant HU; Magee D; Sato M; Turner RT
    Endocrinology; 1994 May; 134(5):2283-8. PubMed ID: 8156931
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor.
    Levenson AS; Jordan VC
    Cancer Res; 1998 May; 58(9):1872-5. PubMed ID: 9581827
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Longitudinal and cross-sectional analysis of raloxifene effects on tibiae from ovariectomized aged rats.
    Sato M; Kim J; Short LL; Slemenda CW; Bryant HU
    J Pharmacol Exp Ther; 1995 Mar; 272(3):1252-9. PubMed ID: 7891341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estrogen supplementation modulates effects of the endocrine disrupting pollutant PCB126 in rat bone and uterus: diverging effects in ovariectomized and intact animals.
    Lind PM; Eriksen EF; Lind L; Orberg J; Sahlin L
    Toxicology; 2004 Jul; 199(2-3):129-36. PubMed ID: 15147787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential effects of estrogen and raloxifene on messenger RNA and matrix metalloproteinase 2 activity in the rat uterus.
    Helvering LM; Adrian MD; Geiser AG; Estrem ST; Wei T; Huang S; Chen P; Dow ER; Calley JN; Dodge JA; Grese TA; Jones SA; Halladay DL; Miles RR; Onyia JE; Ma YL; Sato M; Bryant HU
    Biol Reprod; 2005 Apr; 72(4):830-41. PubMed ID: 15576828
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estrogen and selective estrogen receptor modulator regulation of insulin-like growth factor binding protein 5 in the rat uterus.
    Andrade PM; Silva ID; Borra RC; Lima GR; Baracat EC
    Gynecol Endocrinol; 2002 Aug; 16(4):265-70. PubMed ID: 12396554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.